BioSpectrum India Magazine November issue BioSpectrum India Magazine - Page 28

28 COVERStory BioSpectrum | November 2017 | investors are thinking twice or thrice before investing in this area, as it has more incubation time,” said Dr Shama Bhat by adding that new areas of potential growth are Molecular Diagnostics, Microarray based tests, New Generation Sequencing (NGS), Hybridization and FISH, PCR, POC, Pharmaco-genomics, and Smart- phone based diagnostic products. On sharing his views on newer technologies Pavan Choudary, Director General, Medical Technology Association India said, “The medical technology is a wide spectrum ranging from syringes to cyclotrons; from urine bags to highly developed ultrasonics. As we are moving towards the spectrum, the technology is becoming more and more intricate. So in the simpler side of the spectrum, right now we have greater scope in the global market. As you move towards MAJOR PLAYERS IN INDIAN MARKET  Hindustan Syringes & Medical Devices  Opto Circuits (India)  Wipro GE Healthcare  3M  Medtronic  Johnson & Johnson  Becton Dickinson  Abbott Vascular  Bausch & Lomb  Baxter  Zimmer India  Edwards Life Sciences  St. Jude Medical (now a part of Abbott)  Stryker  Baxter  Boston Scientific  BPL Healthcare India  Sushrut Surgicals  Trivitron Diagnostics  Accurex Biomedical 